Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Apyx Medical (APYX) Net Income towards Common Stockholders (2016 - 2026)

Apyx Medical filings provide 15 years of Net Income towards Common Stockholders readings, the most recent being -$1.3 million for Q4 2025.

  • On a quarterly basis, Net Income towards Common Stockholders rose 71.93% to -$1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$11.2 million, a 52.22% increase, with the full-year FY2025 number at -$11.2 million, up 52.22% from a year prior.
  • Net Income towards Common Stockholders hit -$1.3 million in Q4 2025 for Apyx Medical, up from -$2.0 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$1.0 million in Q2 2023 to a low of -$9.6 million in Q4 2023.
  • Median Net Income towards Common Stockholders over the past 5 years was -$4.6 million (2023), compared with a mean of -$4.6 million.
  • Biggest five-year swings in Net Income towards Common Stockholders: soared 81.3% in 2023 and later crashed 543.38% in 2024.
  • Apyx Medical's Net Income towards Common Stockholders stood at -$2.0 million in 2021, then crashed by 201.74% to -$6.1 million in 2022, then tumbled by 58.4% to -$9.6 million in 2023, then skyrocketed by 51.83% to -$4.6 million in 2024, then soared by 71.93% to -$1.3 million in 2025.
  • The last three reported values for Net Income towards Common Stockholders were -$1.3 million (Q4 2025), -$2.0 million (Q3 2025), and -$3.8 million (Q2 2025) per Business Quant data.